The Polynucleotide Is A Plasmid Or Episome Patents (Class 435/476)
  • Patent number: 11186857
    Abstract: The invention relates to a method for modifying a template double stranded polynucleotide, especially for characterisation using nanopore sequencing. The method produces from the template a plurality of modified double stranded polynucleotides. These modified polynucleotides can then be characterised.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: November 30, 2021
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: David Jackson Stoddart, James White
  • Publication number: 20150093781
    Abstract: The invention relates to an isolated, genetically modified, living non-mammal organism, having increased HMG-CoA-reductase activity compared to the wild type, and having reduced C24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type. The invention further relates to different uses of such an organism, to a test kit comprising such an organism, and to a membrane extract of such an organism.
    Type: Application
    Filed: August 13, 2014
    Publication date: April 2, 2015
    Inventors: Michael Schilling, Christine Lang, Andreas Raab
  • Patent number: 8993327
    Abstract: Systems and methods are described for parallel macromolecular delivery and biochemical/electrochemical interface to whole cells employing carbon nanostructures including nanofibers and nanotubes. A method includes providing a first material on at least a first portion of a first surface of a first tip of a first elongated carbon nanostructure; providing a second material on at least a second portion of a second surface of a second tip of a second elongated carbon nanostructure, the second elongated carbon nanostructure coupled to, and substantially parallel to, the first elongated carbon nanostructure; and penetrating a boundary of a biological sample with at least one member selected from the group consisting of the first tip and the second tip.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: March 31, 2015
    Assignee: UT-Battelle, LLC
    Inventors: Timothy E. McKnight, Anatoli V. Melechko, Guy D. Griffin, Michael A. Guillorn, Vladimir L. Merkulov, Michael L. Simpson
  • Publication number: 20150072395
    Abstract: The present provides selection markers, methods, nucleic acids, and vectors of use in the preparation of recombinant Clostridium spp.
    Type: Application
    Filed: September 12, 2014
    Publication date: March 12, 2015
    Inventors: David Jeffrey Fraser Walker, Shilpa Nagaraju, Michael Koepke, Alexander Paul Mueller
  • Patent number: 8962277
    Abstract: The invention refers to a method of producing a recombinant polypeptide of interest (POI) in a cell culture, comprising genetically engineering a eukaryotic cell line—to specifically cause prolongation of the G2+M cell cycle phase in a pre-culture phase, and—to produce the POI in a producing phase following the pre-culture phase, a high producer cell line and cell culture as well as a method of increasing the yield of a recombinant POI production in a cell culture.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: February 24, 2015
    Assignee: Univeristät für Bodenkultur Wien
    Inventors: Diethard Mattanovich, Martin Dragosits, Brigitte Gasser, Michael Maurer, Michael Sauer
  • Publication number: 20150011008
    Abstract: To provide a technology that solves the above-mentioned problems, and is directly applicable to eukaryotic algal cells with cell-wall, the technology enabling gene transfer and transformation to be performed with high efficiency and good reproducibility irrespective of species of algae.
    Type: Application
    Filed: February 10, 2014
    Publication date: January 8, 2015
    Applicants: Nepa Gene Co., Ltd., Kyoto University
    Inventors: Hideya FUKUZAWA, Takashi Yamano, Kentaro Ifuku, Yasuhiko Hayakawa
  • Patent number: 8921041
    Abstract: The present invention includes devices and methods for transfecting a cell or cell population and dynamic monitoring of cellular events. A variety of microelectronic devices are provide that incorporate functions such as electroporation, modulation of a transmembrane potential and dynamic monitoring of cellular functions and mechanisms.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: December 30, 2014
    Assignee: ACEA Biosciences, Inc.
    Inventors: Xiaobo Wang, Yama A. Abassi, Josephine Atienza, Xiao Xu, Junquan Xu
  • Patent number: 8911721
    Abstract: An object of the present invention is to provide a method of efficiently constructing a gene delivery carrier having a favorable activity and expression efficiency of a protein expressed by a gene introduced by transformation. Moreover, an object of the present invention is to provide a pharmaceutical composition comprising a gene delivery carrier constructed by the construction method and a therapeutic agent for solid tumor comprising the resistant bacterium.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: December 16, 2014
    Assignee: Anaeropharma Science, Inc.
    Inventors: Yuko Shimatani, Yoshinori Hamaji, Hitomi Matsuhashi, Jun Amano, Shun'ichiro Taniguchi, Minoru Fujimori
  • Publication number: 20140363853
    Abstract: Methods of cloning insert sequences into cloning vectors with high efficiency and in the correct orientation are described. In one aspect, the invention features a method of producing a plasmid comprising an insert fragment and a vector fragment in a predetermined orientation. In some embodiments, the method includes cleaving a first nucleotide sequence at a plurality of sites with a first restriction enzyme to generate a first population of nucleotide fragments, the first population of nucleotide fragments comprising insert fragments and non-insert fragments, the insert fragments comprising a non-palindromic overhang at a 5? end, at a 3? end, or at both.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 11, 2014
    Inventor: James Meador, III
  • Patent number: 8894997
    Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of H1N1 influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: November 25, 2014
    Assignees: Vanderbilt University, Icahn School of Medicine at Mount Sinai
    Inventors: James E. Crowe, Christopher F. Basler
  • Publication number: 20140335623
    Abstract: The present invention relates to methods and compositions for engineering sporulating bacterial cells, particularly a cell of the class Clostridia. In particular, the present invention relates to the generation of sporulation deficient bacteria for the generation of industrial superior phenotypes.
    Type: Application
    Filed: May 9, 2014
    Publication date: November 13, 2014
    Inventors: Bryan P. Tracy, Carlos J. Paredes, Eleftherios T. Papoutsakis
  • Patent number: 8877502
    Abstract: The present invention relates to plasmid curing, and particularly to efficient and stress-free methods for displacing resident or endogenous plasmids from a host cell, such as a bacterium. The invention extends to method of displacing a plasmid comprising a post-segregational killing system from a host cell, the method comprising introducing a recombinant nucleic acid molecule into a host cell harboring a plasmid comprising a post-segregational killing (PSK) system, characterized in that the recombinant nucleic acid molecule is adapted to neutralize the toxic effects of the plasmid's post-segregational killing system, and wherein the nucleic acid molecule is also adapted to outcompete or inhibit replication of the plasmid. The invention further extends to recombinant nucleic acid molecules that can be used in this method, as well as further uses of the methods and nucleic acid molecules of the invention.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: November 4, 2014
    Assignee: The University of Birmingham
    Inventor: Christopher Morton Thomas
  • Patent number: 8877209
    Abstract: The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: November 4, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Yoshihiro Kawaoka, Gabriele Neumann
  • Patent number: 8865469
    Abstract: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study of Listeria species and the preparation of Listeria vaccines.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: October 21, 2014
    Assignee: The Regents of the University of California
    Inventors: Daniel A. Portnoy, Richard Lane Calendar, Peter M. Lauer
  • Patent number: 8815779
    Abstract: This invention provides transcription regulatory control sequences, the activity of which function as biomarkers for a variety of biological responses. This invention also provides expression constructs in which a biomarker transcription regulatory sequence is operably linked with a sequence for a reporter. Cells that comprise these expression constructs can be used in assays to identify conditions that modulate activity of the biological response.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: August 26, 2014
    Assignee: SwitchGear Genomics, Inc.
    Inventors: Shelley Force Aldred, Nathan D. Trinklein, Michael Rose, Patrick Collins
  • Patent number: 8809060
    Abstract: The present invention relates to a gene associated with ethanol tolerance, and yeast strains and uses using the same. The yeast strain of this invention may growth under the condition not only with high-concentration ethanol, preferably 6-15% ethanol, but also in high osmotic pressure, preferably 30-40% glucose or sucrose. The present inventors developed yeast strains resistant to high-concentration glucose and ethanol, suggesting that they would be valuably applied to much effective ethanol production, and also be utilized as a superbacteria having tolerance to various stresses for ethanol production with high efficiency.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: August 19, 2014
    Assignee: Ewha University-Industry Collaboration Foundation
    Inventors: Won Ja Choi, Wan Kee Kim
  • USE
    Publication number: 20140199767
    Abstract: The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.
    Type: Application
    Filed: August 6, 2013
    Publication date: July 17, 2014
    Inventors: Rodolphe Barrangou, Patrick Boyaval, Christophe Fremaux, Philippe Horvath, Dennis Romero
  • Patent number: 8778683
    Abstract: The present disclosure provides temperature sensitive essential nucleic acid molecules from a psychrophilic bacterium, proteins encoded by the nucleic acid molecules, as well as recombinant cells into which have been introduced such nucleic acid molecules. The disclosed recombinant cells containing one or more essential nucleic acid molecules from a psychrophilic bacterium are thereby made temperature sensitive, and can be administered to a mammal to induce an immune response in the mammal.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: July 15, 2014
    Assignee: UVic Industry Partnerships Inc.
    Inventor: Francis E. Nano
  • Patent number: 8765426
    Abstract: Zymomonas is unable to synthesize pantothenic acid and requires this essential vitamin in growth medium. Zymomonas strains transformed with an operon for expression of 2-dehydropantoate reductase and aspartate 1-decarboxylase were able to grow in medium lacking pantothenic acid. These strains may be used for ethanol production without pantothenic acid supplementation in seed culture and fermentation media.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: July 1, 2014
    Assignee: E I du Pont de Nemours and Company
    Inventors: Luan Tao, Jean-Francois Tomb, Paul V. Viitanen
  • Publication number: 20140154742
    Abstract: The present invention relates to a recombinant DNA expression/secretion system in E. coli wherein the said system combines the potential of signal peptide-based translocation of recombinant proteins to the periplasmic space of E. coli with membrane brave defective mutants of E. coli to further aid secretion into the extracellular space. The present invention further relates to the expression system which furthermore includes a helper plasmid to drive the expression of translocons to facilitate improved periplasmic secretion of the over-expressed recombinant protein. In addition, this system also facilitates efficient production of specific proteins of interest in E. coli.
    Type: Application
    Filed: April 8, 2012
    Publication date: June 5, 2014
    Inventors: Ayyappan Nair, Sunil Kumar Sukumaran, Shalaka Samant, Gunja Gupta, Suthakarn Pichaimuthu, Ganesh Sambasivam
  • Patent number: 8741604
    Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 3, 2014
    Assignee: Medimmune Limited
    Inventors: Jamie Iain Campbell, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
  • Publication number: 20140141516
    Abstract: The present invention relates to methods and compositions for engineering Clostridia species. In particular, embodiments of the present invention relate to the expression of recombinant resolvase proteins in Clostridia species.
    Type: Application
    Filed: November 27, 2013
    Publication date: May 22, 2014
    Inventors: Bryan P. Tracy, Eleftherios T. Papoutsakis
  • Patent number: 8728798
    Abstract: The technology relates in part to biological methods for producing adipic acid and engineered microorganisms capable of such production.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: May 20, 2014
    Assignee: Verdezyne, Inc.
    Inventors: Stephen Picataggio, Tom Beardslee
  • Publication number: 20140120623
    Abstract: Microalgae are potential energy resources for production of biofuels, such as biodiesel, ethanol, and butanol. A method for enhancing cell growth of microalgae enhances transgenic expression of a bicarbonate transporter (HCO3? transporter) in microalgae and thereby obtains a genetically modified microalgae capable of enhanced inorganic carbon fixation, efficient photosynthesis, and expeditious cell growth. The genetically modified microalgae are fit for use in biofuel production.
    Type: Application
    Filed: April 23, 2013
    Publication date: May 1, 2014
    Applicant: Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan
    Inventors: Jia-Baau Wang, Sheng-Hsin Chou, Te-Jin Chow, Tse-Min Lee, Hsiang-Yen Su, Hsiang-Hsu Chou, Yuan-Ting Hsu, Yu-Rong Pan
  • Publication number: 20140106458
    Abstract: The present invention provides novel C. botulinum conjugatively transmissible plasmids and methods of use thereof. Specifically, described herein are novel, conjugatively transmissible clostridial plasmids which are capable of being transferred among and between clostridial species. The novel plasmids of the present invention therefore permits the delivery of heterologous clostridial genes into a clostridial host, such as C. botulinum, and the expression of genes of interest in that host, including clostridial toxins and the nontoxigenic components of the toxin complex, toxin fragments, or antigenic portions thereof, in a way both that ensures abundant expression and facilitates purification. Furthermore, toxins with altered structures, chimeric, hybrid toxins, and other toxin derivatives valuable in medicine could be synthesized in this system.
    Type: Application
    Filed: December 4, 2013
    Publication date: April 17, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Eric A. Johnson, Kristin M. Marshall, Marite Bradshaw
  • Patent number: 8679822
    Abstract: Xylose-utilizing Zymomonas strains studied were found to accumulate ribulose when grown in xylose-containing media. Engineering these strains to increase ribose-5-phosphate isomerase activity led to reduced ribulose accumulation, improved growth, improved xylose utilization, and increased ethanol production.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: March 25, 2014
    Assignee: E I du Pont de Nemours and Company
    Inventors: Perry G. Caimi, Laura McCole, Luan Tao, Jean-Francois Tomb, Paul V. Viitanen
  • Patent number: 8663948
    Abstract: The object is to provide a transformant which can produce a heterologous protein having a structurally controlled O-linked sugar chain having an O-Man-Gal disaccharide structure, a method for producing the transformant by using Schizosaccharomyces pombe as the host, and provide a host for producing the transformant and a method for producing an O-glycosylated heterologous protein. An Schizosaccharomyces pombe host having no omh1 gene or an inactivated omh1 gene in its chromosomes for producing an O-glycosylated heterologous protein having an O-linked sugar chain having an O-Man-Gal disaccharide structure by expression of the heterologous protein by a genetic engineering technique and subsequent glycosylation of the expressed heterologous protein. A transformant from the host, a method for producing the transformant and a method for producing an O-glycosylated heterologous protein by using the transformant.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: March 4, 2014
    Assignee: Asahi Glass Company, Limited
    Inventors: Kaoru Takegawa, Hideki Tohda, Chihiro Hama
  • Publication number: 20140024086
    Abstract: The subject invention pertains to the discovery that the NADH-dependent propanediol oxidoreductase (FucO) can reduce furfural. This allows for a new approach to improve furfural tolerance in bacterial and/or yeast cells used to produce desired products. Thus, novel biocatalysts (bacterial, fungal or yeast cells) exhibiting increased tolerance to furfural and 5-hydroxymethylfurfural (5-HMF) are provided as are methods of making and using such biocatalysts for the production of a desired product.
    Type: Application
    Filed: March 29, 2012
    Publication date: January 23, 2014
    Inventors: Elliot N. Miller, Xueli Zhang, Lorraine P. Yomano, Xuan Wang, Keelnatham T. Shanmugam, Lonnie O'Neal Ingram
  • Patent number: 8623652
    Abstract: A system for ligase-free cloning and/or expressing a target gene is described herein. A preferred version of the invention includes an E. coli host. The host preferably includes a T7 RNA polymerase gene comprising a T7gpl coding sequence, a lacUV5 promoter, and a lac operator. The host preferably further includes a lacI gene comprising a lacI coding sequence with an ATG start codon, a promoter derived from the lacql allele, and a translational enhancer derived from a 5? RNA leader sequence of T7 gene 10. The invention further includes a low-copy plasmid vector comprising a T7 promoter a lac operator operationally linked to the T7 promoter. The system is configured to inhibit target gene expression when uninduced and to permit gene expression upon induction by auto-induction.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: January 7, 2014
    Assignee: Lucigen Corporation
    Inventors: Eric Steinmetz, Ronald Godiska, David A. Mead
  • Patent number: 8609420
    Abstract: Provided are methods for introducing a molecule of interest into a plant cell having a cell wall by using a QD-peptide conjugate having a quantum dot (QD) with one or more cell penetrating peptides (CPPs). Methods are provided for genetically or otherwise modifying plants and for treating or preventing disease in plant cells comprising a cell wall.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: December 17, 2013
    Assignee: Dow AgroSciences, LLC.
    Inventors: Jayakumar P. Samuel, Narasimha C. Samboju, Kerrm Y. Yau, Gaofeng Lin, Steven R. Webb, Frank Burroughs
  • Patent number: 8603808
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro sand fly Lu. longipalpis salivary antigens that elicit an immune response in animal or human against Leishmania, vaccine compositions comprising said vectors and/or Lu. longipalpis salivary polypeptides, methods of vaccination against Leishmania, and kits for use with such methods and compositions.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: December 10, 2013
    Assignees: Merial Limited, The United States of America As Represented by The Secretary of the Department of Health and Human Services
    Inventors: Laurent Bernard Fischer, Jesus G. Valenzuela, Jose Ribeiro, Shaden Kamhawi
  • Publication number: 20130323803
    Abstract: The present invention relates to compositions and methods for stable transformation of green microalgae and for production of transgenic green microalgae and/or cyanobacteria that produce extremophile enzymes as co-products during the growth of the green microalgae and/or cyanobacteria for lipid biofuel production. Thus, the present invention provides nucleic acid constructs and methods of transformation useful in the production of stably transformed green microalgae and/or cyanobacteria expressing extremophile enzymes in combination with lipid production for biofuel.
    Type: Application
    Filed: February 3, 2012
    Publication date: December 5, 2013
    Applicant: North Carolina State University
    Inventors: Amy Michele Grunden, Heike Inge Ada Sederoff
  • Patent number: 8586295
    Abstract: This present invention provides a method for monitoring ARV resistance, to determine viral fitness, and to forecast possible drug failure. The method provides improved personalized HIV/AIDS care to the patient-physician over existing assays at a reduced cost. This set of assays will utilize the same PCR amplicon of the patient HIV genome, which encompasses all of the drug targeted HIV-1 genes (polPR-RT-IN-envgp120-gp41) and not just PR-RT as with the prior systems. The greatest advantage of this method over previous is the rapid cloning of this amplicon into an HIV-1 genome vector through yeast recombination/gap repair. The vectors can be directly passed from yeast to mammalian cell line which has been specifically engineered to produce replication competent HIV-1 particles and to test susceptibility to all ARVs, i.e. PRIs, NRTIs, NNRTIs, T20, as well as entry and integrase inhibitors in development/clinical trials.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: November 19, 2013
    Assignee: Case Western Reserve University
    Inventor: Eric J. Arts
  • Patent number: 8574909
    Abstract: The invention relates to a strain of the yeast Saccharomyces cerevisiae which, owing to deletion of the genomic sequences, no longer synthesizes hexose transporters and, as a consequence, can no longer grow on substrates with hexoses as the only carbon source, and whose ability of growing on a substrate with a hexose as the only carbon source is restored when it expresses a GLUT4 gene.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: November 5, 2013
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Guenter Mueller, Klaus-Peter Koller, Eckhard Boles, Roman Niedbal, Silke Dlugai
  • Publication number: 20130288251
    Abstract: The present invention relates to a nucleic acid comprising a Lactococcus CRISPR repeat region and/or a Lactococcus CRISPR spacer region.
    Type: Application
    Filed: October 20, 2011
    Publication date: October 31, 2013
    Inventors: Philippe Horvath, Dennis Romero, Anne M. Millen
  • Publication number: 20130280810
    Abstract: The present invention is related to a method for the selection of recombinant clones having integrated a gene of interest and a nucleotide sequence encoding a functional antidote protein to a toxic molecule, wherein said recombinant clones are the ones which survive following their integration into a host cell comprising in its genome a nucleotide sequence encoding said toxic molecule. The present invention is also related to a nucleic acid construct, a vector comprising said nucleic acid construct, a host cell and a cloning and/or sequencing kit for performing said method.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 24, 2013
    Inventors: Philippe Gabant, Laurence Van Melderen, Cedric Yves Szpirer
  • Publication number: 20130259834
    Abstract: Methods and compositions for targeted delivery of biotherapeutics are provided. The compositions comprise bile-sensitive St. thermophilus bacteria modified to release a biotherapeutic agent following bile exposure. Biotherapeutic agents released by the St. thermophilus bacteria disclosed herein include AQ and AQR rich peptides. Methods of the invention comprise administering to a subject a St. thermophilus bacterium modified to release a biotherapeutic agent following bile exposure. Administration of the St. thermophilus bacterium promotes a desired therapeutic response. The bacterium may be modified to express and release AQ or AQR rich peptides which subsequently inhibit cellular apoptosis or reduce mucosal damage. Thus, methods of the invention find use in treating or preventing a variety of gastrointestinal disorders including C. difficile infection and antibiotic-associated diarrhea.
    Type: Application
    Filed: May 19, 2011
    Publication date: October 3, 2013
    Inventors: Todd R. Klaenhammer, Richard L. Guerrant, Glynis L. Kolling, Evelyn Durmaz, Michael P. Timko, Cirle Alcantara Warren
  • Publication number: 20130224865
    Abstract: Novel antimicrobial agents that can serve as replacements to conventional pharmaceutical antibiotics are disclosed. The antimicrobial agents comprise conjugatively transmissible plasmids that kill targeted pathogenic bacteria, but are not harmful to donor bacteria. Two types of lethal transmissible plasmids are disclosed. One type kills recipient bacteria by unchecked (“runaway”) replication in the recipient cells and is prevented from occurring in donor cells. Another type kills recipient bacteria by expressing a gene that produces a product detrimental or lethal to recipient bacterial cells, that gene being prevented from expression in donor cells.
    Type: Application
    Filed: April 2, 2013
    Publication date: August 29, 2013
    Inventor: Wisconsin Alumni Research Foundation
  • Patent number: 8486701
    Abstract: A method for modulating cell differentiation capabilities using heterologous gene expression. Some embodiments of the invention relate to a method for inducing a cardiac progenitor cell by delivering a reprogramming factor to the cell, wherein the reprogramming factor comprises ETS2 or a combination of ETS2 and Mesp1.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: July 16, 2013
    Assignees: University of Houston, Texas Heart Institute, The Texas A&M University System
    Inventors: Robert J. Schwartz, Vladimir N. Potaman, Jose Francisco Islas
  • Publication number: 20130180012
    Abstract: An isolated protein which is at least partially encoded by a polynucleotide sequence encoding a novel sulfotransferase is provided together with a composition which includes the isolated protein. A transgenic organism transformed by a polynucleotide encoding a protein which is at least partially encoded by a novel sulfotransferase is also provided. The invention also includes a process for in-vivo and in-vitro making a sulfated polysaccharide from an unsulfated polysaccharide or increasing the sulfur content of an already sulfated polysaccharide.
    Type: Application
    Filed: April 11, 2011
    Publication date: July 11, 2013
    Inventors: Shoshana Arad, Lena Plesser, Yaakov Weinstein
  • Patent number: 8465945
    Abstract: The present invention includes a method to produce a recombinant mite Group 1 protein in a methyltrophic yeast or an Escherichia coli microorganism. The present invention also relates to a recombinant mite Group 1 protein obtained by such a method, such a recombinant protein being able to selectively bind IgE or cause proliferation of a T cell that proliferate in response to a native mite Group 1 protein. Also included in the present invention is the use of such a recombinant mite Group 1 protein to detect mite allergy or to reduce an allergic response to a mite Group 1 protein. The present invention also includes novel mite Group 1 nucleic acid molecules, proteins, recombinant molecules, and recombinant cells, as well as uses thereof.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: June 18, 2013
    Assignee: Merck Patent GmbH
    Inventors: Elaine A. Best, Martin J. McDermott
  • Publication number: 20130149785
    Abstract: The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.
    Type: Application
    Filed: November 19, 2012
    Publication date: June 13, 2013
    Inventor: The Johns Hopkins University
  • Publication number: 20130143282
    Abstract: Some aspects of this invention provide engineered microbes for oil production. Methods for microbe engineering and for use of engineered microbes are also provided herein. In some embodiments, microbes are provided that are engineered to modulate a combination of rate-controlling steps of lipid synthesis, for example, a combination of a step generating metabolites, acetyl-CoA, ATP or NADPH for lipid synthesis (a push step), and a step sequestering a product or an intermediate of a lipid synthesis pathway that mediates feedback inhibition of lipid synthesis (a pull step). Such push-and-pull engineered microbes exhibit greatly enhanced conversion yields and TAG synthesis and storage properties.
    Type: Application
    Filed: October 19, 2012
    Publication date: June 6, 2013
    Applicant: Massachusetts Institute of Technology
    Inventor: Massachusetts Institute of Technology
  • Patent number: 8445268
    Abstract: The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic vaccine for people with genetic high risk.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: May 21, 2013
    Assignee: ViroMed Co., Ltd.
    Inventors: Joon Youb Lee, Dong-Hyeon Kim, Yeonseok Chung, Sun-Young Chang, Kyung-Chul Lee, Chang-Yuil Kang
  • Patent number: 8435537
    Abstract: Expression system of peptides on the bacterial surface characterized in that membrane-binding region the conserved sequence of the MSP1a protein of Anaplasma marginale.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: May 7, 2013
    Assignees: Consejo Superior de Investigaciones Científicas, Universidad de Castilla la Mancha
    Inventors: José De La Fuenta García, Mario Manuel Canales García-Menocal
  • Patent number: 8435777
    Abstract: A synthetic gene devoid of CpG nucleotide derived by genetic engineering from copepod luciferases genes that code for a new secreted luciferase with a strong bioluminescent signal. This gene display advantageous properties to be used as a reporter genes in cell based assays.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: May 7, 2013
    Assignee: Cayla
    Inventors: Jean Paul Reynes, Céline Casteran, Daniel Drocourt, Gérard Tiraby
  • Patent number: 8431373
    Abstract: Disclosed are recombinant microorganisms for producing organic acids. The recombinant microorganisms express a polypeptide that has the enzymatic activity of an enzyme that is utilized in the pentose phosphate cycle. The recombinant microorganism may include recombinant Actinobacillus succinogenes that has been transformed to express a Zwischenferment (Zwf) gene. The recombinant microorganisms may be useful in fermentation processes for producing organic acids such as succinic acid and lactic acid. Also disclosed are novel plasmids that are useful for transforming microorganisms to produce recombinant microorganisms that express enzymes such as Zwf.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: April 30, 2013
    Assignee: Michigan Biotechnology Institute
    Inventors: Jian Yi, Susanne Kleff, Michael V. Guettler
  • Publication number: 20130089522
    Abstract: This invention is related to bacterial engineering and the heterologous expression of useful compounds. In particular, the invention relates to a heterologous host that has been engineered for expression of a gene which is capable of polyketide or non-ribosomal peptide synthesis. Methods of treating cancer are also disclosed.
    Type: Application
    Filed: December 17, 2010
    Publication date: April 11, 2013
    Applicant: GENE BRIDGES GMBH
    Inventors: Youming Zhang, Jun Fu, Xiaoying Bian, Francis Stewart, Rolf Muller
  • Publication number: 20130078694
    Abstract: Zymomonas is unable to synthesize pantothenic acid and requires this essential vitamin in growth medium. Zymomonas strains transformed with an operon for expression of 2-dehydropantoate reductase and aspartate 1-decarboxylase were able to grow in medium lacking pantothenic acid. These strains may be used for ethanol production without pantothenic acid supplementation in seed culture and fermentation media.
    Type: Application
    Filed: March 29, 2012
    Publication date: March 28, 2013
    Inventors: LUAN TAO, Jean-Francois Tomb, Paul V. Viitanen
  • Publication number: 20130059334
    Abstract: The present invention generally relates to the production of industrially relevant quantities of selenoprotein enzymes in eukaryotic cell cultures. More specifically, the present invention generally relates to the production of such enzymes wherein one or more catalytic cysteine or serine residues are mutagenically replaced by selenocysteine.
    Type: Application
    Filed: June 28, 2012
    Publication date: March 7, 2013
    Inventors: Richard Sayre, Hangsik Moon